Investor Presentaiton

CSL112 Apolipoprotein A-I (human) - AEGIS-II Objective: to evaluate the efficacy and safety of CSL112 on reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), or stroke For the primary efficacy endpoint at 90 days, the trial did not meet the threshold for statistical significance There are no plans for a near-term regulatory filing Additional analyses are ongoing to understand the complete data and determine next steps Study results will be presented at the American College of Cardiology (ACC) Scientific Sessions, 6 April 2024, and published in a peer-reviewed journal 12 Driven by Our Promise CSL

View entire presentation